{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:35:25Z","timestamp":1791408925871,"version":"4.3.3"},"reference-count":92,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH\/NCCIH","doi-asserted-by":"publisher","award":["R01AT012053-03"],"award-info":[{"award-number":["R01AT012053-03"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PA Options for Wellness","award":["R01AT012053-03"],"award-info":[{"award-number":["R01AT012053-03"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Ulcerative colitis (UC) is an autoimmune disorder characterized by inflammation of the mucosa that gives rise to a disrupted epithelial morphology. Persistent or recurrent inflammation and the debilitating nature of the associated symptoms make treatment of UC challenging. Cannabinoids derived from Cannabis sativa L. have been used for treatment of gastrointestinal disorders due to the wide-ranging therapeutic benefits of these compounds. Methods: We evaluated a commercial hemp extract, high in cannabigerol (CBG) and cannabidiol (CBD), as a novel treatment for UC symptoms using the dextran sodium sulfate (DSS) model in mice. Hemp extract was administered via two different routes of administration, intraperitoneal (i.p) and oral (p.o). Results: Specifically, we observed that cannabinoid treatment reduced damage to the colonic epithelium. We also observed that CBG\/CBD rich hemp extracts help reduce pain-related responses in these animals. Conclusions: Together, the data suggest that cannabinoid administration has the potential to be an effective alternate therapeutic option for UC management.<\/jats:p>","DOI":"10.3390\/jcm14176095","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T15:03:14Z","timestamp":1756393394000},"page":"6095","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Orally Administered CBD\/CBG Hemp Extract Reduces Severity of Ulcerative Colitis and Pain in a Murine Model"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0177-2286","authenticated-orcid":false,"given":"Shivani S.","family":"Godbole","sequence":"first","affiliation":[{"name":"Department of Neuroscience & Experimental Therapeutics, Penn State College of Medicine, Hershey, PA 17033, USA"},{"name":"Center for Cannabis & Natural Product Pharmaceutics, Penn State College of Medicine, Hershey, PA 17033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4902-4292","authenticated-orcid":false,"given":"Dongxiao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neuroscience & Experimental Therapeutics, Penn State College of Medicine, Hershey, PA 17033, USA"},{"name":"Center for Cannabis & Natural Product Pharmaceutics, Penn State College of Medicine, Hershey, PA 17033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Coates","sequence":"additional","affiliation":[{"name":"Department of Neuroscience & Experimental Therapeutics, Penn State College of Medicine, Hershey, PA 17033, USA"},{"name":"Center for Cannabis & Natural Product Pharmaceutics, Penn State College of Medicine, Hershey, PA 17033, USA"},{"name":"Department of Medicine, Penn State College of Medicine, Hershey, PA 17033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria J.","family":"Himmelberger","sequence":"additional","affiliation":[{"name":"Department of Neuroscience & Experimental Therapeutics, Penn State College of Medicine, Hershey, PA 17033, USA"},{"name":"Center for Cannabis & Natural Product Pharmaceutics, Penn State College of Medicine, Hershey, PA 17033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4165-2377","authenticated-orcid":false,"given":"Diana E.","family":"Roopchand","sequence":"additional","affiliation":[{"name":"Department of Food Science, Rutgers University, New Brunswick, NJ 08901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9413-9852","authenticated-orcid":false,"given":"Wesley M.","family":"Raup-Konsavage","sequence":"additional","affiliation":[{"name":"Department of Neuroscience & Experimental Therapeutics, Penn State College of Medicine, Hershey, PA 17033, USA"},{"name":"Center for Cannabis & Natural Product Pharmaceutics, Penn State College of Medicine, Hershey, PA 17033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Gubatan, J., Kulkarni, C.V., Talamantes, S.M., Temby, M., Fardeen, T., and Sinha, S.R. (2023). Dietary Exposures and Interventions in Inflammatory Bowel Disease: Current Evidence and Emerging Concepts. Nutrients, 15.","DOI":"10.3390\/nu15030579"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e51721","DOI":"10.1002\/eji.202451721","article-title":"Current and Emerging Autoantibodies in Ulcerative Colitis","volume":"55","author":"Faber","year":"2025","journal-title":"Eur. J. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Omer, M., Omer, O.I., Ali, M., and Mohamed, I.O. (2025). Therapeutic Potentials of Phytochemicals in the Treatment of Ulcerative Colitis: Results from Animal Model Interventional Studies. J. Am. Nutr. Assoc., 1\u201313.","DOI":"10.1080\/27697061.2025.2532078"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.21037\/tgh-24-117","article-title":"Machine Learning in the Differential Diagnosis of Ulcerative Colitis and Crohn\u2019s Disease: A Systematic Review","volume":"10","author":"Huang","year":"2025","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"101995","DOI":"10.1016\/j.bpg.2025.101995","article-title":"The Role of Diet in Inflammatory Bowel Disease: A Comprehensive Review of the Literature","volume":"77","author":"Faggiani","year":"2025","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19","author":"Silverberg","year":"2005","journal-title":"Can. J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100851","DOI":"10.1016\/j.disamonth.2019.02.004","article-title":"A Comprehensive Review and Update on Ulcerative Colitis","volume":"65","author":"Gajendran","year":"2019","journal-title":"Dis. Mon."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Melhem, H., Regan-Komito, D., and Niess, J.H. (2021). Mucins Dynamics in Physiological and Pathological Conditions. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222413642"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"113544","DOI":"10.1016\/j.intimp.2024.113544","article-title":"Novel Targets for Mucosal Healing in Inflammatory Bowel Disease Therapy","volume":"144","author":"Mansouri","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative Colitis","volume":"402","author":"Honap","year":"2023","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101990","DOI":"10.1016\/j.bpg.2025.101990","article-title":"Treatment Targets in IBD: Is It Time for New Strategies?","volume":"77","author":"Fanizzi","year":"2025","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"otad055","DOI":"10.1093\/crocol\/otad055","article-title":"Abdominal Pain in Inflammatory Bowel Disease: An Evidence-Based, Multidisciplinary Review","volume":"5","author":"Coates","year":"2023","journal-title":"Crohn\u2019s Colitis 360"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00384-020-03727-3","article-title":"Abdominal Pain in Quiescent Inflammatory Bowel Disease","volume":"36","author":"Coates","year":"2021","journal-title":"Int. J. Color. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1089\/can.2020.0155","article-title":"Symptoms and Extraintestinal Manifestations in Active Cannabis Users with Inflammatory Bowel Disease","volume":"7","author":"Coates","year":"2022","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Bogale, K., Maheshwari, P., Kang, M., Gorrepati, V.S., Dalessio, S., Walter, V., Stuart, A., Koltun, W., Bernasko, N., and Tinsley, A. (2022). Symptoms Associated with Healthcare Resource Utilization in the Setting of Inflammatory Bowel Disease. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-14838-y"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1080\/03007995.2019.1631058","article-title":"Dose Escalation and Switching of Biologics in Ulcerative Colitis: A Systematic Literature Review in Real-World Evidence","volume":"35","author":"Gemayel","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Velikova, T., Sekulovski, M., and Peshevska-Sekulovska, M. (2024). Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development. Antibodies, 13.","DOI":"10.3390\/antib13010016"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Anil, S.M., Peeri, H., and Koltai, H. (2022). Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.908198"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.4155\/fmc.09.93","article-title":"Cannabinoids as Novel Anti-Inflammatory Drugs","volume":"1","author":"Nagarkatti","year":"2009","journal-title":"Future Med. Chem."},{"key":"ref_20","first-page":"100463","article-title":"Cannabinoids and Neuroinflammation: Therapeutic Implications","volume":"12","author":"Leonard","year":"2023","journal-title":"J. Affect. Disord. Rep."},{"key":"ref_21","first-page":"598","article-title":"Use of Medical Cannabis in Patients with Inflammatory Bowel Disease","volume":"14","author":"Kinnucan","year":"2018","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/ibd\/izad151","article-title":"The Impact of Cannabis Use on Clinical Outcomes in Inflammatory Bowel Disease: A Population-Based Longitudinal Cohort Study","volume":"30","author":"Glickman","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"103593","DOI":"10.1016\/j.jpet.2025.103593","article-title":"Better Together? Individual and Synergistic Effects of Noneuphorigenic Cannabinoids on Visceral Sensation","volume":"392","author":"Coates","year":"2025","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1526-5900(00)90082-8","article-title":"Cannabinoids Modulate Pain by Multiple Mechanisms of Action","volume":"1","author":"Richardson","year":"2000","journal-title":"J. Pain"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/FBP.0000000000000627","article-title":"Antinociceptive Effects of Minor Cannabinoids, Terpenes and Flavonoids in Cannabis","volume":"33","author":"Rodriguez","year":"2022","journal-title":"Behav. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2017.206","article-title":"CB1 Receptor Signaling in the Brain: Extracting Specificity from Ubiquity","volume":"43","author":"Bains","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1146\/annurev.pa.35.040195.003135","article-title":"Pharmacology of Cannabinoid Receptors","volume":"35","author":"Howlett","year":"1995","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1017\/S1462399409000957","article-title":"Emerging Role of the Cannabinoid Receptor CB2 in Immune Regulation: Therapeutic Prospects for Neuroinflammation","volume":"11","author":"Cabral","year":"2009","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bcp.2008.09.014","article-title":"A Role for CB2 Receptors in Anandamide Signalling Pathways Involved in the Regulation of IL-12 and IL-23 in Microglial Cells","volume":"77","author":"Correa","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Hryhorowicz, S., Kaczmarek-Ry\u015b, M., Zieli\u0144ska, A., Scott, R.J., S\u0142omski, R., and P\u0142awski, A. (2021). Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease\u2014A Systematic Review. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.790803"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Tartakover Matalon, S., Azar, S., Meiri, D., Hadar, R., Nemirovski, A., Abu Jabal, N., Konikoff, F.M., Drucker, L., Tam, J., and Naftali, T. (2021). Endocannabinoid Levels in Ulcerative Colitis Patients Correlate with Clinical Parameters and Are Affected by Cannabis Consumption. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.685289"},{"key":"ref_32","first-page":"89","article-title":"Mice Lacking Cannabinoid CB1-, CB2-Receptors or Both Receptors Show Increased Susceptibility to Trinitrobenzene Sulfonic Acid (TNBS)-Induced Colitis","volume":"61","author":"Engel","year":"2010","journal-title":"J. Physiol. Pharmacol. Off. J. Pol. Physiol. Soc."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1124\/jpet.124.002204","article-title":"High Cannabigerol Hemp Extract Moderates Colitis and Modulates the Microbiome in an Inflammatory Bowel Disease Model","volume":"390","author":"Anderson","year":"2024","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/ibd\/izy014","article-title":"The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis","volume":"24","author":"Couch","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Pagano, E., Capasso, R., Piscitelli, F., Romano, B., Parisi, O.A., Finizio, S., Lauritano, A., Marzo, V.D., Izzo, A.A., and Borrelli, F. (2016). An Orally Active Cannabis Extract with High Content in Cannabidiol Attenuates Chemically-Induced Intestinal Inflammation and Hypermotility in the Mouse. Front. Pharmacol., 7.","DOI":"10.3389\/fphar.2016.00341"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00213-011-2415-0","article-title":"Plasma and Brain Pharmacokinetic Profile of Cannabidiol (CBD), Cannabidivarine (CBDV), \u03949-Tetrahydrocannabivarin (THCV) and Cannabigerol (CBG) in Rats and Mice Following Oral and Intraperitoneal Administration and CBD Action on Obsessive\u2013Compulsive Behaviour","volume":"219","author":"Deiana","year":"2012","journal-title":"Psychopharmacology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/0471142735.im1525s104","article-title":"Dextran Sulfate Sodium (DSS)-Induced Colitis in Mice","volume":"104","author":"Chassaing","year":"2014","journal-title":"Curr. Protoc. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1128\/MCB.00548-12","article-title":"The Myc 3\u2032 Wnt-Responsive Element Regulates Homeostasis and Regeneration in the Mouse Intestinal Tract","volume":"32","author":"Konsavage","year":"2012","journal-title":"Mol. Cell. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1007\/s10620-013-2686-x","article-title":"The Myc 3\u2032 Wnt Responsive Element Regulates Neutrophil Recruitment after Acute Colonic Injury in Mice","volume":"58","author":"Konsavage","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s10620-015-3852-0","article-title":"A Role for MYC in Lithium-Stimulated Repair of the Colonic Epithelium After DSS-Induced Damage in Mice","volume":"61","author":"Cooper","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/ejp.2016","article-title":"Cannabigerol (CBG) Attenuates Mechanical Hypersensitivity Elicited by Chemotherapy-induced Peripheral Neuropathy","volume":"26","author":"Sepulveda","year":"2022","journal-title":"Eur. J. Pain"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0304-3959(01)00275-5","article-title":"A New Model of Visceral Pain and Referred Hyperalgesia in the Mouse","volume":"92","author":"Laird","year":"2001","journal-title":"Pain"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Est\u00e9vez, S., Gris, G., De La Puente, B., Carceller, A., and Mart\u00ednez, V. (2021). Intestinal Inflammation-Associated Hypersensitivity Is Attenuated in a DSS Model of Colitis in Sigma-1 Knockout C57BL\/6 Mice. Biomed. Pharmacother., 143.","DOI":"10.1016\/j.biopha.2021.112126"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/1715163518779409","article-title":"Patients\u2019 Perceptions and Use of Natural Health Products","volume":"151","author":"Barry","year":"2018","journal-title":"Can. Pharm. J. CPJ Rev. Pharm. Can. RPC"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1592\/phco.20.1.83.34658","article-title":"Assessment of Patients\u2019 Perceptions and Beliefs Regarding Herbal Therapies","volume":"20","author":"Klepser","year":"2000","journal-title":"Pharmacotherapy"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/01639360802634043","article-title":"Use and Safety Perceptions Regarding Herbal Supplements: A Study of Older Persons in Southeast Idaho","volume":"28","author":"Snyder","year":"2009","journal-title":"J. Nutr. Elder."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ctim.2006.06.007","article-title":"Differences in Perceived Risks and Benefits of Herbal, over-the-Counter Conventional, and Prescribed Conventional, Medicines, and the Implications of This for the Safe and Effective Use of Herbal Products","volume":"15","author":"Lynch","year":"2007","journal-title":"Complement. Ther. Med."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Chiba, T., and Tanemura, N. (2022). Differences in the Perception of Dietary Supplements between Dietary Supplement\/Medicine Users and Non-Users. Nutrients, 14.","DOI":"10.3390\/nu14194114"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5414\/CP203857","article-title":"Dietary Supplements\u2014Use and Safety Perception: A Study among Hospitalized Dermatology Patients","volume":"59","author":"Tsokeva","year":"2021","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4103\/0975-7406.199349","article-title":"A Qualitative Insight on Complementary and Alternative Medicines Used by Hypertensive Patients","volume":"8","author":"Ibrahim","year":"2016","journal-title":"J. Pharm. Bioallied Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000517425","article-title":"Cannabis and Cannabis Derivatives for Abdominal Pain Management in Inflammatory Bowel Disease","volume":"4","author":"Bogale","year":"2021","journal-title":"Med. Cannabis Cannabinoids"},{"key":"ref_52","first-page":"668","article-title":"Therapeutic Use of Cannabis in Inflammatory Bowel Disease","volume":"12","author":"Ahmed","year":"2016","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/ecco-jcc\/jjy185","article-title":"Cannabis, Cannabinoids, and the Endocannabinoid System-Is There Therapeutic Potential for Inflammatory Bowel Disease?","volume":"13","author":"Ambrose","year":"2019","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_54","first-page":"e36148","article-title":"The Use of Cannabinoids in the Treatment of Inflammatory Bowel Disease (IBD): A Review of the Literature","volume":"15","author":"Nduma","year":"2023","journal-title":"Cureus"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1007\/s10620-019-05763-8","article-title":"Is Cannabis of Potential Value as a Therapeutic for Inflammatory Bowel Disease?","volume":"64","author":"Naftali","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jcmgh.2021.08.010","article-title":"Chronic Inflammation in Ulcerative Colitis Causes Long-Term Changes in Goblet Cell Function","volume":"13","author":"Singh","year":"2022","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Leoncini, G., Cari, L., Ronchetti, S., Donato, F., Caruso, L., Calaf\u00e0, C., and Villanacci, V. (2024). Mucin Expression Profiles in Ulcerative Colitis: New Insights on the Histological Mucosal Healing. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031858"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/gast.2001.29694","article-title":"Epithelial Barrier Defects in Ulcerative Colitis: Characterization and Quantification by Electrophysiological Imaging","volume":"121","author":"Gitter","year":"2001","journal-title":"Gastroenterology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/can.2020.0109","article-title":"Cannabidiol-Driven Alterations to Inflammatory Protein Landscape of Lipopolysaccharide-Activated Macrophages In Vitro May Be Mediated by Autophagy and Oxidative Stress","volume":"6","author":"Yeisley","year":"2021","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.taap.2019.02.011","article-title":"DMH-CBD, a Cannabidiol Analog with Reduced Cytotoxicity, Inhibits TNF Production by Targeting NF-kB Activity Dependent on A2A Receptor","volume":"368","author":"Silva","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"114713","DOI":"10.1016\/j.taap.2019.114713","article-title":"Cannabidiol Differentially Regulates Basal and LPS-Induced Inflammatory Responses in Macrophages, Lung Epithelial Cells, and Fibroblasts","volume":"382","author":"Muthumalage","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.bcp.2013.01.017","article-title":"Beneficial Effect of the Non-Psychotropic Plant Cannabinoid Cannabigerol on Experimental Inflammatory Bowel Disease","volume":"85","author":"Borrelli","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Li, S., Li, W., Malhi, N.K., Huang, J., Li, Q., Zhou, Z., Wang, R., Peng, J., Yin, T., and Wang, H. (2024). Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. Molecules, 29.","DOI":"10.3390\/molecules29225471"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Farrell, K.E., Callister, R.J., and Keely, S. (2014). Understanding and Targeting Centrally Mediated Visceral Pain in Inflammatory Bowel Disease. Front. Pharmacol., 5.","DOI":"10.3389\/fphar.2014.00027"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/MEG.0000000000002354","article-title":"Somatosensory Assessments in Patients with Inflammatory Bowel Disease: A Cross-Sectional Study Examining Pain Processing Pathways and the Role of Multiple Patient Factors","volume":"34","author":"Falling","year":"2022","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3181\/00379727-182-42360","article-title":"Hormonal Regulation of the Release of Plasminogen Activators and of a Specific Activator Inhibitor from Endometrial Tissue in Culture","volume":"182","author":"Andersson","year":"1986","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.2174\/0113892010261502231102040149","article-title":"Systematic Review on Herbal Preparations for Controlling Visceral Hypersensitivity in Functional Gastrointestinal Disorders","volume":"25","author":"Lashgari","year":"2024","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"102047","DOI":"10.1016\/j.pupt.2021.102047","article-title":"The Anti-Inflammatory Effects of Cannabidiol and Cannabigerol Alone, and in Combination","volume":"69","author":"Horniman","year":"2021","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/jbmr.4902","article-title":"Cannabidiol and Cannabigerol, Nonpsychotropic Cannabinoids, as Analgesics That Effectively Manage Bone Fracture Pain and Promote Healing in Mice","volume":"38","author":"Khajuria","year":"2023","journal-title":"J. Bone Miner. Res."},{"key":"ref_70","first-page":"100777","article-title":"Oral Cannabidiol (CBD) as Add-on to Paracetamol for Painful Chronic Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","volume":"35","author":"Pramhas","year":"2023","journal-title":"Lancet Reg. Health\u2014Eur."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11916-023-01101-w","article-title":"Medical Cannabis for Chronic Nonmalignant Pain Management","volume":"27","author":"Hameed","year":"2023","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_72","first-page":"CD012182","article-title":"Cannabis-Based Medicines for Chronic Neuropathic Pain in Adults","volume":"3","author":"Phillips","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Gamble, L.-J., Boesch, J.M., Frye, C.W., Schwark, W.S., Mann, S., Wolfe, L., Brown, H., Berthelsen, E.S., and Wakshlag, J.J. (2018). Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs. Front. Vet. Sci., 5.","DOI":"10.3389\/fvets.2018.00165"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"C\u00e1sedas, G., de Yarza-Sancho, M., and L\u00f3pez, V. (2024). Cannabidiol (CBD): A Systematic Review of Clinical and Preclinical Evidence in the Treatment of Pain. Pharmaceuticals, 17.","DOI":"10.3390\/ph17111438"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/j.1476-5381.2012.01879.x","article-title":"Inhibitory Effect of Cannabichromene, a Major Non-Psychotropic Cannabinoid Extracted from Cannabis Sativa, on Inflammation-Induced Hypermotility in Mice","volume":"166","author":"Izzo","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Wen, Y., Wang, Z., Zhang, R., Zhu, Y., Lin, G., Li, R., and Zhang, J. (2023). The Antinociceptive Activity and Mechanism of Action of Cannabigerol. Biomed. Pharmacother., 158.","DOI":"10.1016\/j.biopha.2022.114163"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic Properties of Cannabidiol at 5-HT1a Receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/bph.14440","article-title":"Allosteric and Orthosteric Pharmacology of Cannabidiol and Cannabidiol-dimethylheptyl at the Type 1 and Type 2 Cannabinoid Receptors","volume":"176","author":"Tham","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Raup-Konsavage, W.M., Sepulveda, D.E., Wang, J., Dokholyan, N.V., Vrana, K.E., and Graziane, N.M. (2023). Antinociceptive Effects of Cannabichromene (CBC) in Mice: Insights from von Frey, Tail-Flick, Formalin, and Acetone Tests. Biomedicines, 12.","DOI":"10.3390\/biomedicines12010083"},{"key":"ref_80","first-page":"e94","article-title":"Activation of CB2 Receptors by (\u2212)-Cannabichromene but Not (+)-Cannabichromene","volume":"10","author":"Udoh","year":"2024","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1111\/bph.14815","article-title":"Cannabichromene Is a Cannabinoid CB2 Receptor Agonist","volume":"176","author":"Udoh","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/bph.12120","article-title":"The Cannabinoid TRPA1 Agonist Cannabichromene Inhibits Nitric Oxide Production in Macrophages and Ameliorates Murine Colitis","volume":"169","author":"Romano","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1007\/s11095-009-9860-z","article-title":"Intestinal Lymphatic Transport Enhances the Post-Prandial Oral Bioavailability of a Novel Cannabinoid Receptor Agonist via Avoidance of First-Pass Metabolism","volume":"26","author":"Trevaskis","year":"2009","journal-title":"Pharm. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/17425255.2022.2099837","article-title":"Strategies for Enhancing the Oral Bioavailability of Cannabinoids","volume":"18","author":"Domb","year":"2022","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Lacerda, M., Carona, A., Castanheira, S., Falc\u00e3o, A., Bicker, J., and Fortuna, A. (2025). Pharmacokinetics of Non-Psychotropic Phytocannabinoids. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17020236"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1089\/can.2015.0012","article-title":"Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy","volume":"1","year":"2016","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1124\/dmd.120.000350","article-title":"Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol","volume":"49","author":"Beers","year":"2021","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"ref_88","first-page":"1","article-title":"Mechanisms of Action and Pharmacokinetics of Cannabis","volume":"25","author":"Chayasirisobhon","year":"2020","journal-title":"Perm. J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/cpt.2973","article-title":"Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants","volume":"114","author":"Bansal","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"103828","DOI":"10.1016\/j.ajp.2023.103828","article-title":"Adverse Events of Epidiolex: A Real-World Drug Safety Surveillance Study Based on the FDA Adverse Event Reporting System (FAERS) Database","volume":"90","author":"Zhou","year":"2023","journal-title":"Asian J. Psychiatry"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e0008","DOI":"10.5041\/RMMJ.10390","article-title":"Cannabis for the Treatment of Inflammatory Bowel Disease: A True Medicine or a False Promise?","volume":"11","author":"Naftali","year":"2020","journal-title":"Rambam Maimonides Med. J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1097\/MEG.0000000000001565","article-title":"Medical Cannabis for Inflammatory Bowel Disease: Real-Life Experience of Mode of Consumption and Assessment of Side-Effects","volume":"31","author":"Naftali","year":"2019","journal-title":"Eur. J. Gastroenterol. Hepatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/17\/6095\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:34:41Z","timestamp":1760034881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/17\/6095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":92,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["jcm14176095"],"URL":"https:\/\/doi.org\/10.3390\/jcm14176095","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]}}}